Positive clinical outcomes for PriMatrix Dermal Repair Scaffold for the management of diabetic foot ulcers
Integra Life Sciences Holding Corporation a leading global medical technology company announced positive clinical outcomes for PriMatrix Dermal Repair Scaffold for the management of hard to heal diabetic foot ulcers. This study is one of the largest DFU randomized controlled trials ever completed with more than 100 patients per treatment group and demonstrated that in most cases, one application of PriMatrix plus standard of care healed 60% of DFUs in 12 weeks versus 35% of DFUs that healed in 12 weeks with SOC for the per protocol analysis.